Isola Therapeutics Inc.

Isola Therapeutics Inc., a for-profit medical device and therapeutic development company based in Minneapolis, Minnesota, operates as a prime contractor developing specialized medical countermeasures for chemical and biological threats under full-and-open federal procurement, with no set-aside designations across its award footprint.

Isola's federal customer base concentrates entirely within the Department of Health and Human Services. The Office of the Assistant Secretary for Preparedness and Response (ASPR) has funded two awards totaling $8.2 million in combined potential value, while the National Cancer Institute has placed one award valued at $455 thousand. These three awards represent 100% of the vendor's tracked federal footprint and account for $8.7 million in combined potential value, with all obligated dollars drawn down.

Isola's capability portfolio centers on therapeutic interventions for chemical exposure and cancer treatment. The vendor's primary work stream targets pulmonary injuries from chemical agents: a $7.49 million definitive firm fixed-price contract awarded by ASPR on May 1, 2026, funds development of nebulization therapy as a medical countermeasure to prevent and treat pulmonary foam resulting from inhalation of chemical agents, with performance running through October 31, 2028. An earlier $750 thousand ASPR contract awarded on July 12, 2023, under the REDIRECT (Repurposing Drugs in Response to Chemical Threats) initiative supported research and development for endobronchial lavage (EBL) as a preventative and therapeutic intervention for lung damage from pulmonary chemical agents, with ultimate completion dated July 11, 2025. Separately, the National Cancer Institute awarded a $455 thousand Small Business Innovation Research Phase I contract on September 15, 2022, for drug delivery by endoesophageal lavage (EEL) to treat esophageal cancer, with completion dated March 14, 2025.

Activity shows episodic award placement: one award in 2022, one in 2023, and one in 2026. The $7.49 million ASPR contract represents the vendor's largest single award and anchors the near-term pipeline through October 2028; the two earlier awards are at or past their performance completion dates. Service Contract Inventory reporting captures $250 thousand in invoiced federal services revenue in FY2024 across approximately 1.2 FTEs, reflecting early-stage government-paid labor on the ASPR nebulization therapy contract at median hourly rates around $98.81/hr. Isola has not appeared as a named subcontractor across the SCI dataset and operates exclusively as a prime contractor, with no sub-engagement across its federal service contracts.